Overview
Background
Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).
Grants
Category 1: $14.3M Category 3: $131.8M
Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.
Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).
Availability
- Professor Andrew Martin is:
- Available for supervision
Research impacts
Research Achievements and Collaborations: Has made original, innovative, and distinguished contributions to methodological research, as well as the design, conduct, analysis, interpretation, and dissemination of clinical research that has had an impact at an international level policy, practice, and subsequent research programs. Has been responsible for the provision of statistical leadership to collaborative trials groups to design, undertake, analyse, and report on clinical trials, as well as promoting investigator-initiated research activities. 2020-2024 Scopus/SciVal author publication metrics: FWCI of 5.21, 51% in top 10% most cited worldwide, 39% international collaboration 3,763 citations (10,934 overall). Received the 2020 ACTA (Australian Clinical Trials Alliance) Statistics in Trials Interest Group Excellence in Trial Statistics Award for ENZAMET Trial. Research funding in last 5 years: $3.1M category 1 and $76.7M category 3.
Contributions to the Field: Led methodological research with international impact. Examples in the last 5 years focus on the topic of changes to the design of ongoing trials. This work has been cited in the CONSERVE 2021 Statement (JAMA. 2021;326(3):257-265 FWCI 7.38; top 1% of general medical journals). Also co-published innovative method for appropriately adjusting estimates of effect obtained from trials that terminate early based on the results of an interim analysis (Statistical Methods in Medical Research – top 11% for statistics journals). Co-designed andled the statistical aspects of design, conduct, analysis, and interpretation of many trial. Two key examples in the last 5 years include ENZAMET and TheraP. (1) ENZAMET study selected for plenary presentation at ASCO (peak international clinical oncology conference attended by over 30,000 international delegates). Am second author for both main N Engl J Med paper (2019;381:121) (journal ranked top 1% general medicine), the quality of life J Clin Oncol paper (2022;40:837-46) (journal ranked top 2% cancer research), and the follow-up Lancet Oncol paper (2022;23:1389) (journal ranked top 1% cancer research). Results were used in support of successful registration of enzalutamide with US FDA in this indication and have been incorporated into US and European treatment guidelines. (2) TheraP evaluated efficacy of cutting-edge targeted radiopharmaceutical (Lu-PSMA) in advance prostate cancer that delivers radiation to cells expressing the prostate-specific membrane antigen. Selected for oral presentation at highly prestigious ASCO 2020 and ASCO GU 2021 conferences. Second senior author of The Lancet paper (2021;397:797) (journal ranked top 1% general medicine). Has led to 2 additional RCTs of Lu-PSMA that I co-designed. One (ENZA-p) was just published in Lancet Oncol (2024 Apr 12:S1470-2045(24)00135-9) (journal ranked top 1% cancer research).
Works
Search Professor Andrew Martin’s works on UQ eSpace
2021
Journal Article
Reacting to prognostic covariate imbalance in randomised controlled trials
Coskinas, Xanthi, Schou, I. Manjula, Simes, John and Martin, Andrew (2021). Reacting to prognostic covariate imbalance in randomised controlled trials. Contemporary Clinical Trials, 110 106544, 1-7. doi: 10.1016/j.cct.2021.106544
2021
Journal Article
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Emmett, Louise, Subramaniam, Shalini, Joshua, Anthony M., Crumbaker, Megan, Martin, Andrew, Zhang, Alison Y., Rana, Nisha, Langford, Ailsa, Mitchell, Jenna, Yip, Sonia, Francis, Roslyn, Hofman, Michael S., Sandhu, Shahneen, Azad, Arun, Gedye, Craig, McJannett, Margaret, Stockler, Martin R. and Davis, Ian D. (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128 (5), 642-651. doi: 10.1111/bju.15491
2021
Journal Article
Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study
Mazza, Danielle, Lin, Xiaoping, Walter, Fiona M., Young, Jane M., Barnes, David J., Mitchell, Paul L., Brijnath, Bianca, Martin, Andrew, O'Byrne, Kenneth J. and Emery, Jon D. (2021). Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study. European Journal of Cancer Care, 30 (6) e13492, 1-11. doi: 10.1111/ecc.13492
2021
Journal Article
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, Christopher J., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Reaume, M. Neil, Sandhu, Shahneen K., Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia ... Davis, Ian D. (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80 (3), 275-279. doi: 10.1016/j.eururo.2021.05.016
2021
Journal Article
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3
2021
Journal Article
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
Blinman, Prunella, Martin, Andrew, Jefford, Michael, Goldstein, David, Boadle, David, Morris, Michelle, Tebbutt, Niall, Aiken, Christine, Harkin, Andrea, Segelov, Eva, Haydon, Andrew, Iveson, Tim and Stockler, Martin R. (2021). Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 5 (1) pkaa107, 1-6. doi: 10.1093/jncics/pkaa107
2021
Journal Article
Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial
Trinh, Terry, Park, Susanna B., Murray, Jenna, Pickering, Hannah, Lin, Cindy S.-Y., Martin, Andrew, Friedlander, Michael, Kiernan, Matthew C., Goldstein, David and Krishnan, Arun V. (2021). Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. Supportive Care in Cancer, 29 (2), 1103-1110. doi: 10.1007/s00520-020-05591-x
2021
Journal Article
Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK
Lau, David K., Luk, Ian Y., Jenkins, Laura J., Martin, Andrew, Williams, David S., Schoffer, Kael L., Chionh, Fiona, Buchert, Michael, Sjoquist, Katrin, Boussioutas, Alex, Hayes, Sarah A., Ernst, Matthias, Weickhardt, Andrew J., Pavlakis, Nick, Tebbutt, Niall C. and Mariadason, John M. (2021). Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK. Molecular Cancer Therapeutics, 20 (4), 704-715. doi: 10.1158/1535-7163.MCT-20-0836
2020
Journal Article
Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma
Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair W. S., Meade, Angela, Goh, Jeffrey, Gurney, Howard, Harrison, Michelle, Fife, Kate, Eisen, Tim, Blinman, Prunella and Stockler, Martin R. (2020). Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 4 (4), 185-195. doi: 10.3233/KCA-200104
2020
Journal Article
Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?
Vasista, Anuradha, Stockler, Martin R., Martin, Andrew, Lawrence, Nicola J. and Kiely, Belinda E. (2020). Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?. Internal Medicine Journal, 50 (12), 1492-1499. doi: 10.1111/imj.14739
2020
Conference Publication
DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., Roncolato, F., McJannett, M., Horvath, L., Sengupta, S., Hughes, S., McDermott, R., Catto, J., Kelly, P., Vapiwala, N., Parulekar, W. R., Morgan, S., Rendon, R. A. and Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ESMO Virtual Congress, Electr Network, Sep 19-Oct 18, 2020. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2020.08.2088
2020
Journal Article
The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer
Whitford, Hayley S., Kalinowski, Pawel, Schembri, Adrian, Grimison, Peter, Stockler, Martin, Martin, Andrew, Toner, Guy C., Davis, Ian D., Maruff, Paul and Olver, Ian N. (2020). The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, 28 (7), 3081-3091. doi: 10.1007/s00520-019-05095-3
2020
Journal Article
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients
Smith-Uffen, M. E.S., Johnson, S. B., Martin, A. J., Tattersall, M. H.N., Stockler, M. R., Bell, M. L., Detering, K., Clayton, J. M., Silvester, W., Clarke, S., Vaccaro, L., Beale, P. and Kiely, B. E. (2020). Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. Supportive Care in Cancer, 28 (7), 3399-3407. doi: 10.1007/s00520-019-05158-5
2020
Journal Article
Changes to aspects of ongoing randomised controlled trials with fixed designs
Coskinas, Xanthi, Simes, John, Schou, Manjula, Schou, Manjula and Martin, Andrew James (2020). Changes to aspects of ongoing randomised controlled trials with fixed designs. Trials, 21 (1) 457, 1-8. doi: 10.1186/s13063-020-04374-3
2020
Journal Article
The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial
Tarnow-Mordi, William O, Abdel-Latif, Mohamed E, Martin, Andrew, Pammi, Mohan, Robledo, Kristy, Manzoni, Paolo, Osborn, David, Lui, Kei, Keech, Anthony, Hague, Wendy, Ghadge, Alpana, Travadi, Javeed, Brown, Rebecca, Darlow, Brian A, Liley, Helen, Pritchard, Margo, Kochar, Anu, Isaacs, David, Gordon, Adrienne, Askie, Lisa, Cruz, Melinda, Schindler, Tim, Dixon, Kerry, Deshpande, Girish, Tracy, Mark, Schofield, Deborah, Austin, Nicola, Sinn, John, Simes, R John ... Espinoza, D. (2020). The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial. The Lancet Child and Adolescent Health, 4 (6), 444-454. doi: 10.1016/S2352-4642(20)30093-6
2020
Journal Article
Interventions commenced by early infancy to prevent childhood obesity—The EPOCH Collaboration: An individual participant data prospective meta-analysis of four randomized controlled trials
Askie, Lisa M., Espinoza, David, Martin, Andrew, Daniels, Lynne A., Mihrshahi, Seema, Taylor, Rachael, Wen, Li Ming, Campbell, Karen, Hesketh, Kylie D., Rissel, Chris, Taylor, Barry, Magarey, Anthea, Seidler, Anna Lene, Hunter, Kylie E. and Baur, Louise A. (2020). Interventions commenced by early infancy to prevent childhood obesity—The EPOCH Collaboration: An individual participant data prospective meta-analysis of four randomized controlled trials. Pediatric Obesity, 15 (6) e12618, 1-10. doi: 10.1111/ijpo.12618
2020
Journal Article
Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences
Moth, Erin B., Kiely, Belinda E., Martin, Andrew, Naganathan, Vasi, Della-Fiorentina, Stephen, Honeyball, Florian, Zielinski, Rob, Steer, Christopher, Mandaliya, Hiren, Ragunathan, Abiramy and Blinman, Prunella (2020). Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences. Journal of Geriatric Oncology, 11 (4), 626-632. doi: 10.1016/j.jgo.2019.07.026
2020
Journal Article
Estimating survival time in older adults receiving chemotherapy for advanced cancer
Moth, Erin B., Blinman, Prunella, Stefanic, Natalie, Naganathan, Vasi, Grimison, Peter, Stockler, Martin R., Beale, Philip, Martin, Andrew and Kiely, Belinda E. (2020). Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of Geriatric Oncology, 11 (4), 617-625. doi: 10.1016/j.jgo.2019.08.013
2020
Journal Article
Association of Bolus Feeding With Splanchnic and Cerebral Oxygen Utilization Efficiency Among Premature Infants With Anemia and After Blood Transfusion
Kiran Kumar Balegar, V., Jayawardhana, Madhuka, Martin, Andrew J., de Chazal, Philip and Nanan, Ralph K.H. (2020). Association of Bolus Feeding With Splanchnic and Cerebral Oxygen Utilization Efficiency Among Premature Infants With Anemia and After Blood Transfusion. JAMA Network Open, 3 (2), 1-14. doi: 10.1001/jamanetworkopen.2020.0149
2020
Conference Publication
P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)
Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Frazier, A. Lindsay, Mazhar, Danish, Ford, Kate, Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Troon, Simon, Hanning, Fritha J., Birtle, Alison Jane, Wheater, Matthew James, Huddart, Robert A., White, Jeff D., Spunt, Sheri L. and Grimison, Peter S. (2020). P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA USA, 13-15 February 2020. Alexandria, VA: American Society of Clinical Oncology.
Funding
Current funding
Supervision
Availability
- Professor Andrew Martin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Advanced methods for biomarker informed endometrial cancer
Associate Advisor
Other advisors: Dr Eva Baxter, Dr Zoe West, Professor Andreas Obermair
Media
Enquiries
For media enquiries about Professor Andrew Martin's areas of expertise, story ideas and help finding experts, contact our Media team: